ASP5541

DRUG3 trials

Sponsors

Astellas Pharma Global Development Inc., Astellas Pharma Global Development, Inc.

Conditions

Metastatic Castration-Resistant Prostate CancerMetastatic Hormone Sensitive Prostate CancerProstate Cancer

Phase 1

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

RecruitingNCT07339267

Astellas Pharma Global Development, Inc.Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer, Prostate Cancer

Start: 2026-01-20End: 2028-12-31Target: 12Updated: 2026-02-18

Phase 2

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

RecruitingNCT07005154

Astellas Pharma Global Development, Inc.Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer, Prostate Cancer

Start: 2025-06-19End: 2032-05-31Target: 218Updated: 2026-04-02

A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants with Advanced Prostate Cancer

Not yet recruitingCTIS2024-517653-27-00

Astellas Pharma Global Development Inc.Prostate Cancer

Target: 89Updated: 2026-01-20